In parallel, comprehensive molecular profiling of the tumor tissue was performed to identify potentially actionable genomic alterations; however, no targetable mutations (e.g., BRAF, NRAS, c-KIT) were identified, thereby limiting the use of targeted therapies. The gene discussed is NRAS; the disease is neoplasm.